Logo
Eloquence Fine with Lidocaine

Eloquence Fine with Lidocaine

Eloquence

Dermal filler – hyaluronic acid injectable
  • Eloquence Fine is described by multiple European distributors as a CE Certified Medical Class II hyaluronic acid dermal filler.
  • Manufactured by Jetema, a globally recognised Korean company that also produces other HA filler brands (e.g. Regenovue, e.p.t.q.), under stringent quality and safety standards.
  • Produced according to the IX Essential Process criteria outlined in Eloquence technical literature, including safe raw materials, high Purity HA, high viscoelasticity, uniform particle size, minimal residual chemical catalysts, aseptic production, endotoxin level <0.1 EU/ml, physiological pH/osmolarity and optimised injection pressure.
  • Uses ZEEP Technology (Zero Endotoxin & BDDE Entire Process) and Jetema’s Downing Process to minimise residual BDDE, control endotoxin content and achieve uniform particle size and high viscoelasticity.
  • Manufacturing and quality management aligned with internationally recognised medical device quality standards (e.g. ISO 13485 Based systems) for injectable HA fillers.
Superficial / fine-line hyaluronic acid dermal filler with lidocaine

Description

Eloquence Fine with Lidocaine is a CE-marked, lightweight hyaluronic acid dermal filler produced by the Korean company Jetema. Formulated with cross-linked, non-animal hyaluronic acid and 0.3% lidocaine, it is designed for the correction and rejuvenation of superficial and fine lines and wrinkles, especially delicate areas such as crow’s feet at the outer corners of the eyes and lines beneath the eyes. Eloquence Fine can also be used in most areas of the face, including for subtle lip plumping and definition, gentle marionette-line softening and neck-line improvement. With a high HA concentration of 24 mg/ml and a smooth, low-viscosity gel structure, it delivers natural-looking, refined results while the lidocaine improves patient comfort during injection. Effects of treatment are typically visible immediately and can last for many months, with some distributors and The Crystal Pharmacy indicating results of up to around 8 months depending on the area treated and individual factors.

Bnefits

  • Lightweight, low-viscosity hyaluronic acid filler specifically designed for superficial and fine lines and wrinkles.
  • Ideal for delicate regions such as crow’s feet, periorbital fine lines and superficial lines beneath the eyes.
  • Can be used to rejuvenate most areas of the face with subtle, natural-looking correction rather than heavy volumisation.
  • Suitable for gentle lip plumping, lip border definition and fine perioral lines in appropriately selected patients.
  • Contains lidocaine (3 mg/ml, 0.3%) to minimise injection discomfort and improve overall treatment tolerance.
  • High hyaluronic acid concentration (24 mg/ml) combined with high viscoelasticity for effective tissue support and fresh, rested appearance.
  • Smooth, homogeneous monophasic gel for easy, controlled injection and good tissue integration.
  • Low endotoxin content (<0.1 EU/ml) and optimised cross-linking process (ZEEP and Downing Process technologies) designed to reduce swelling and risk of side effects.
  • Medical Class II, CE-certified dermal filler manufactured according to stringent quality and safety criteria for professional aesthetic use.

Indications

  • Correction and rejuvenation of superficial and fine facial lines and wrinkles.
  • Crow’s feet and fine lines around the outer corners of the eyes.
  • Fine lines beneath the eyes and other periorbital expression lines in suitable candidates.
  • Forehead lines and glabellar (frown) lines where superficial treatment is appropriate.
  • Marionette lines and perioral (smoker’s) lines when treated with fine, superficial injections.
  • Gentle lip hydration, subtle lip augmentation and contour enhancement.
  • Mild neck folds and fine lines on the neck in carefully selected patients.
  • General improvement of skin texture and fine-line reduction in superficial dermis, as judged appropriate by the treating clinician.

Composition

  • Cross-linked hyaluronic acid 24 mg/ml (non-animal origin).
  • Lidocaine hydrochloride 3 mg/ml (0.3%) as a local anaesthetic.
  • Physiological buffer solution with pH and osmolarity adjusted to approximate human tissue (exact excipients not fully disclosed; typical for HA fillers are phosphate-buffered saline and stabilising agents).
  • Endotoxin content less than 0.1 EU/ml, according to manufacturer and distributor information for the Eloquence range.
  • Residual BDDE (cross-linking agent) minimised through ZEEP (Zero Endotoxin & BDDE Entire Process) technology and optimised cross-linking processes.

Formulation

  • Monophasic, cross-linked hyaluronic acid gel with lidocaine for intradermal implantation.
  • Hyaluronic acid concentration: 24 mg/ml.
  • Lidocaine concentration: 3 mg/ml (0.3%).
  • Syringe volume: pre-filled 1.1 ml sterile syringe (1 ampoule-syringe 1.1 ml).
  • Needles supplied: typically 1 x 27G and 1 x 30G sterile needles per box.
  • Lightweight, smooth gel with relatively low viscosity and cohesive properties optimised for superficial dermal injection and delicate areas.
  • Medical Class II device in the Eloquence filler portfolio.

Packaging

  • Single-use, pre-filled glass syringe containing 1.1 ml of cross-linked hyaluronic acid gel with lidocaine.
  • Each retail box typically includes 1 x 1.1 ml syringe and 2 sterile needles (1 x 27G and 1 x 30G) in a blister tray.
  • Outer carton marked with product name (Eloquence Fine), volume, batch number, expiry date and CE marking.
  • Sterile, pyrogen-free, single-use medical device for professional use only; supplied individually or in larger wholesale quantities by aesthetic pharmacies and distributors.

Usage

  • For professional use only – Eloquence Fine with Lidocaine should be administered exclusively by suitably trained and qualified medical or aesthetic practitioners with appropriate knowledge of facial anatomy and dermal filler techniques.
  • Conduct a full consultation, medical history and informed consent before treatment; assess indications, contraindications and patient expectations.
  • Cleanse and disinfect the treatment area according to clinical protocol. Additional topical anaesthetic may be used if desired, taking into account that the product already contains lidocaine.
  • Select an appropriate injection technique (e.g. linear threading, serial puncture, fanning, micro-droplet) for superficial dermal placement, using the supplied 27G or 30G needle or an appropriate microcannula.
  • Inject slowly with minimal pressure, delivering small aliquots in the superficial to mid-dermis depending on indication, and avoiding overcorrection.
  • Aspirate in line with the practitioner’s protocol and constantly observe tissue response and patient feedback to reduce risk of intravascular injection.
  • Gently massage and mould the product as needed to achieve smooth, even distribution and a natural contour, avoiding excessive pressure that may displace the filler.
  • Limit total volume per area based on anatomical considerations and safety; do not exceed recommended amounts in delicate regions such as periorbital or perioral zones.
  • Provide post-treatment advice, including avoiding makeup on treated areas for the recommended period, refraining from intense heat or cold exposure and strenuous exercise for at least 24 hours (or as per clinic protocol), and not massaging the treated areas unless instructed.
  • Educate patients about possible side effects and warning signs of complications (e.g. severe pain, blanching, dusky or mottled skin, visual changes) and instruct them to seek immediate medical attention if such symptoms occur.
  • Discard any unused product, used syringes and needles in approved clinical sharps and medical waste containers in accordance with local regulations.

Contraindications

  • Known hypersensitivity or allergy to hyaluronic acid, lidocaine or other amide-type local anaesthetics, or to any of the excipients.
  • History of severe allergic reactions or anaphylaxis to injectable products unless carefully assessed and managed by an experienced clinician.
  • Presence of active skin infection, inflammation or lesions (e.g. acne, herpes simplex) at or near the planned injection sites.
  • Autoimmune diseases, immunodeficiency or other systemic conditions where filler treatment is considered inappropriate by the prescribing clinician.
  • Bleeding disorders, significant coagulation abnormalities or current use of high-dose anticoagulant therapy that cannot be adjusted, unless benefits clearly outweigh risks and specialist advice is sought.
  • Pregnancy and breastfeeding – hyaluronic acid dermal fillers with lidocaine are generally not recommended due to insufficient safety data.
  • History of hypertrophic scarring or keloid formation, or significant connective tissue disorders, unless treatment is deemed appropriate and low risk by a specialist.
  • Previous permanent or certain semi-permanent fillers in the same area where there is a risk of interactions, nodularity or unpredictable results.
  • Any other condition, medication or circumstance that, in the professional judgement of the treating clinician, renders dermal filler treatment unsafe or unsuitable.

Adverse Effects

  • Common, usually transient injection-site reactions such as redness (erythema), swelling, tenderness, pain, itching, bruising, slight discolouration or increased sensitivity at the treatment site; these typically resolve within a few days.
  • Temporary lumps, nodules or unevenness at the injection area if the gel is not evenly distributed or if localised overfilling occurs; often manageable with massage or, if persistent, with hyaluronidase by trained clinicians.
  • Short-term firmness or a feeling of tightness in the treated area as the product integrates.
  • Local hypersensitivity or allergic-type reactions, which may present with prolonged swelling, redness or induration and require medical management.
  • Infection at the injection site, particularly if aseptic technique is not rigorously followed, presenting with warmth, pain, redness and swelling.
  • Vascular compromise or occlusion if product is inadvertently injected into or compresses a blood vessel; symptoms can include severe pain, blanching, livedo, dusky discolouration or tissue necrosis if untreated and require immediate emergency management including hyaluronidase and other measures according to established protocols.
  • Very rare but serious adverse events reported with hyaluronic acid fillers in general, such as visual disturbances, visual loss or stroke from embolic vascular events; practitioners must be trained in prevention, recognition and urgent treatment pathways.
  • Delayed inflammatory reactions, granuloma formation or biofilm-related complications have been rarely reported with HA fillers and may require pharmacological and/or procedural intervention.
  • Transient numbness or altered sensation due to lidocaine or injection trauma, usually resolving spontaneously.

Storage Conditions

  • Store at a controlled room temperature as specified by the manufacturer (commonly between 2 °C and 25 °C); do not freeze.
  • Keep the syringe in its original blister and outer carton until time of use to protect from light and contamination.
  • Do not use the product after the expiry date indicated on the packaging.
  • Do not use if the blister, syringe or needle packaging is damaged, opened or shows signs of compromise.
  • Store out of reach of unauthorised persons and children, in accordance with local regulations for medical devices.
  • Dispose of used syringes, needles and any remaining product as clinical sharps/medical waste according to local requirements.

Duration

Clinical and distributor information indicates that the aesthetic effects of Eloquence Fine typically last several months, with many sources describing a duration of around 6 to 12 months depending on area, technique and individual metabolism. The Crystal Pharmacy and similar suppliers specifically note that visible effects can be seen for up to approximately 8 months in many patients, after which touch-up or repeat treatments may be performed at the clinician\u2019s discretion.

Onset

Results are generally visible immediately after injection due to the volumising effect of the hyaluronic acid gel, with final results becoming more evident over several days as initial swelling subsides and the filler integrates with surrounding tissues. Patients are often reviewed after the initial healing period to evaluate outcomes and determine whether any refinement is required.

Browse more Dermal filler \u2013 hyaluronic acid injectable

Top Treatments

Top Cities in the UK